دورية أكاديمية
Elevation of Neutrophil-to-Lymphocyte Ratio before First-Line Chemotherapy Predicts a Poor Prognosis for Second-Line Chemotherapy in Gastric Cancer
| العنوان: | Elevation of Neutrophil-to-Lymphocyte Ratio before First-Line Chemotherapy Predicts a Poor Prognosis for Second-Line Chemotherapy in Gastric Cancer |
|---|---|
| المؤلفون: | Inoue, Dai, Sekiguchi, Shuhei, Yamagata, Wataru, Maeda, Gen, Yamada, Daiki, Fujiwara, Shun, Itou, Shiori, Kurihara, Masamichi, Hijioka, Yuko, Shimoji, Kohei, Fujiki, Junko, Nakazono, Ayano, Horike, Hideyuki, Yoshioka, Atsushi, Ogura, Yuki, Hatao, Fumihiko, Imamura, Kazuhiro, Namiki, Shin |
| المصدر: | Oncology ; volume 96, issue 3, page 140-146 ; ISSN 0030-2414 1423-0232 |
| بيانات النشر: | S. Karger AG |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Cancer Research, Oncology, General Medicine |
| الوصف: | Objectives: The neutrophil-to-lymphocyte ratio (NLR) has been proposed as an indicator of cancer-related inflammation. The aim of our study was to examine the prognostic value of the NLR for patients with advanced gastric cancer receiving second-line chemotherapy. Methods: The association of overall survival (OS) in second-line chemotherapy and the clinicopathological findings including NLR were analyzed retrospectively. The selection criteria were patients who received second-line chemotherapy between January 2010 and June 2015, had histologically confirmed gastric adenocarcinoma, and were followed up until death or for 180 days or longer. Results: Eighty-six patients met the selection criteria. Multivariate analysis revealed that performance status 2, hemoglobin < 10 g/dL, and NLR before first-line chemotherapy ≥3 were adverse predictive markers. NLR before second-line chemotherapy was not associated with OS. A prognostic model was constructed dividing patients into three groups according to the number of adverse predictive factors: good (no factor), intermediate (one factor), and poor (more than two factors). The median OS for the good, intermediate, and poor groups was 14.3, 7.2, and 4.4 months, respectively ( p < 0.001). Conclusions: Patients with advanced gastric cancer with performance status 2, hemoglobin < 10 g/dL, and NLR before first-line chemotherapy ≥3 are not likely to benefit from second-line chemotherapy. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1159/000493427 |
| الإتاحة: | https://doi.org/10.1159/000493427Test https://www.karger.com/Article/Pdf/493427Test |
| حقوق: | https://www.karger.com/Services/SiteLicensesTest ; https://www.karger.com/Services/SiteLicensesTest |
| رقم الانضمام: | edsbas.4E60A919 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1159/000493427 |
|---|